SC
DSGN icon

Shay Capital’s Design Therapeutics DSGN Stock Holding History

Shay Capital’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-128,305
Closed -$517K – 315
2024
Q1 		$517K Buy
+128,305
New +$343K 0.08% 177

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Shay Capital's DSGN Position: Q2 2024 in Review

Shay Capital sold out of Design Therapeutics (DSGN) in Q2 2024, closing a stake of 128,305 shares — an estimated $517K sold.

Shay Capital first reported a position in DSGN in Q1 2024 and held it in 1 quarter. The position peaked at $517K in Q1 2024. 95 funds tracked by Wall St. Rank hold DSGN as of Q2 2024.

  • Shay Capital reported no remaining Design Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Shay Capital sold 128,305 Design Therapeutics shares in Q2 2024, an estimated $517K.
  • Shay Capital first reported a position in Design Therapeutics in Q1 2024 and held it in 1 quarter.
  • Shay Capital's Design Therapeutics position peaked at $517K in Q1 2024.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2024.

Based on Shay Capital's 13F filing for Q2 2024, filed 14 Aug 2024.